About The Study: In this study, adolescents with obesity prescribed a glucagon-like peptide 1 receptor agonists (GLP1R) had a lower incidence of suicidal ideation or attempts compared with matched patients not prescribed GLP1R who were treated with lifestyle intervention. These results suggest a favorable psychiatric safety profile of GLP1R in adolescents. The detected reduction in hazard ratios for suicidal ideation among adolescents with obesity prescribed GLP1R suggests potential avenues for future research.
Corresponding Author: To contact the corresponding author, Liya Kerem, MD, MSc, email liya.em@gmail.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2024.3812)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.3812?guestAccessKey=30dc2b89-6672-48bd-aba1-1936667825bf&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424
JAMA Pediatrics